Jianshi Technology focuses on R&D, production, sales and service in the field of minimally invasive valve interventional therapy, and strives to provide innovative solutions for doctors and patients. The company is committed to becoming a world-class technology leader in cardiac valve interventional therapy. At present, the company has developed a transcatheter aortic valve replacement system, a transcatheter tricuspid valve replacement system, a transcatheter mitral valve replacement system and a transcatheter mitral valve repair system, among which the tricuspid valve and mitral valve products are internationally leading Status, with more than 30 invention patents and 4 PCT patents. Today, Jianshi Technology Hong Kong Stock Exchange submitted a prospectus.
This article is reprinted from: https://www.itjuzi.com/pre-ipo?comname=%E5%81%A5%E4%B8%96%E7%A7%91%E6%8A%80
This site is for inclusion only, and the copyright belongs to the original author.